Gleevec, Taxotere

TERMINATED · PHASE2 · Gastric Adenocarcinoma

Terminated 4/17/07. Drug sponsor withdrew.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.